Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.37 |
| ▸ | ADH1C | P00326 | 1/20 | 0.37 |
| ▸ | ADH1A | P07327 | 1/20 | 0.37 |
| ▸ | ADH4 | P08319 | 1/20 | 0.37 |
| ▸ | ADH7 | P40394 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 6/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543967 | 0.98 | ADH1B (0.40) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL27705383 | 0.98 | ADH1B (0.40) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL73403 | 0.98 | ADH1B (0.40) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL1451000 | 0.95 | — | — | |
| SCHEMBL456220 | 0.90 | — | — | |
| SCHEMBL17102571 | 0.90 | ADH1B (0.35) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL3025958 | 0.86 | CYP1A2 (0.41) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL3258085 | 0.85 | CYP1A2 (0.45) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL5543638 | 0.85 | CYP1A2 (0.45) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL5541873 | 0.85 | CYP1A2 (0.45) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9648879-B2 | Co-crystal and method for producing same | NIPPON SODA CO., LTD. (JP) | 2017-05-16 | — | — | US | disclosed |
| EP-1719794-B1 | NOVEL POLYMERS AND USES THEREOF | MITSUI CHEMICALS INC (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-20160278380-A1 | CO-CRYSTAL AND METHOD FOR PRODUCING SAME | NIPPON SODA CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
| EP-3069610-A1 | CO-CRYSTAL AND METHOD FOR PRODUCING SAME | Nippon Soda Co., Ltd. (JP) | 2016-09-21 | — | — | EP | disclosed |
| EP-2314583-B1 | NITROGENATED HETEROCYCLIC DERIVATIVE, AND AGRICULTURAL OR HORTICULTURAL BACTERICIDAL AGENT | NIPPON SODA CO (JP) | 2015-02-25 | — | — | EP | disclosed |
| US-8557738-B2 | Nitrogen-containing heterocyclic derivative and fungicide for agricultural and horticultural use | NIPPON SODA CO., LTD. (JP) | 2013-10-15 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7977429-B2 | Polymers and uses thereof | MITSUI CHEMICALS, INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20110136782-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE AND FUNGICIDE FOR AGRICULTURAL AND HORTICULTURAL USE | NIPPON SODA CO., LTD (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| US-6011039-A | USEFUL AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; TREATING HYPERPHAGIA, OBESITY OR DIABETES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-01-04 | — | — | US | disclosed |
| US-5880147-A | Amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prohylactic use | SANKYO COMPANY, LIMITED (JP) | 1999-03-09 | — | — | US | disclosed |
| EP-0889034-A1 | AMINOPYRIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-01-07 | — | — | EP | disclosed |
| EP-0005859-B1 | PROCESS FOR REDUCING METAL ION CONTENT OF AQUEOUS SOLUTIONS | DE NORA PERMELEC S.P.A. (IT) | 1983-02-16 | — | — | EP | disclosed |
| US-4215009-A | COMPLEXING | ORONZIO DENORA IMPIANTI ELETTROCHIMICI S.P.A. (IT) | 1980-07-29 | — | — | US | disclosed |
| EP-0005859-A1 | Process for reducing metal ion content of aqueous solutions | DE NORA PERMELEC S.P.A. (IT) | 1979-12-12 | — | — | EP | disclosed |
| US-3980687-A | Intermediates for the preparation of 17-substituted-Δ4 -gonenes | ROUSSEL-UCLAF (FR) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160278380-A1 | CO-CRYSTAL AND METHOD FOR PRODUCING SAME | DDT, CCDC22, MLN | ADH1B 994/4885ADH1C 650/4885ADH1A 2209/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | ADH1B 1160/4885ADH1C 697/4885ADH1A 211/4885 |
| US-20110136782-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE AND FUNGICIDE FOR AGRICULTURAL AND HORTICULTURAL USE | CBR3, NOS1, CBR1 | ADH1B 2180/4885ADH1C 1553/4885ADH1A 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.